InvestorsHub Logo
Followers 468
Posts 26926
Boards Moderated 2
Alias Born 09/11/2006

Re: surf1944 post# 469

Saturday, 08/04/2012 11:40:29 AM

Saturday, August 04, 2012 11:40:29 AM

Post# of 554
NeurogesX receives additional notice of allowance covering NGX-1998 in U.S.
Theflyonthewall.com – Thu, Aug 2, 2012 9:04 AM EDT.. .

NeurogesX announced it has received an additional notice of allowance from the U.S. Patent and Trademark Office, or USPTO, related to the company's family of patents for NGX-1998, the company's next generation liquid formulation of prescription-strength capsaicin. The allowed patent application expands on the company's patent entitled, "Methods and compositions for administration of TRPV1 agonists." The claims in the allowed application relate to methods of treating capsaicin-responsive conditions with a liquid formulation containing between 10% and 30% by weight of a TRPV1 agonist and certain penetration enhancer combinations. The capsaicin-responsive conditions referenced in the patent application include various types of pain, such as neuropathic pain and pain associated with skin cancer. The patent issuing from this application is expected to expire in 2024.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.